MA40462A - Méthode de traitement de la dépression - Google Patents
Méthode de traitement de la dépressionInfo
- Publication number
- MA40462A MA40462A MA040462A MA40462A MA40462A MA 40462 A MA40462 A MA 40462A MA 040462 A MA040462 A MA 040462A MA 40462 A MA40462 A MA 40462A MA 40462 A MA40462 A MA 40462A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- depression
- snp
- genotype
- patient
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40462A true MA40462A (fr) | 2017-06-21 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040462A MA40462A (fr) | 2014-08-13 | 2015-08-12 | Méthode de traitement de la dépression |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (https=) |
| EP (1) | EP3179993B1 (https=) |
| JP (1) | JP6545788B2 (https=) |
| KR (1) | KR20170040800A (https=) |
| CN (1) | CN106714789A (https=) |
| AU (2) | AU2015301782B2 (https=) |
| CA (1) | CA2957926A1 (https=) |
| IL (2) | IL250490A0 (https=) |
| MA (1) | MA40462A (https=) |
| MX (1) | MX2017001908A (https=) |
| WO (1) | WO2016025581A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| CA2936809A1 (en) * | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| CN107208133A (zh) | 2014-09-15 | 2017-09-26 | 詹森药业有限公司 | 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| MX2020006650A (es) | 2017-12-22 | 2020-11-06 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| CA3127607A1 (en) * | 2019-01-23 | 2020-07-30 | The Regents Of The University Of Michigan | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
| MX2021010683A (es) | 2019-03-05 | 2021-12-10 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| WO2021262871A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
| CN117355302A (zh) | 2021-04-30 | 2024-01-05 | 思维医学股份有限公司 | Lsd盐晶体形式 |
| JP2024529727A (ja) | 2021-08-19 | 2024-08-08 | マインド メディシン， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| AU758679B2 (en) | 1998-07-24 | 2003-03-27 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| AU2003268026A1 (en) | 2002-07-30 | 2004-02-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090306137A1 (en) | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| SI2582366T1 (sl) | 2010-06-15 | 2016-02-29 | Gruenenthal Gmbh | Farmacevtska kombinacija za zdravljenje bolečine |
| KR102035877B1 (ko) * | 2011-11-14 | 2019-10-23 | 알파시그마 에스.피.에이. | 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법 |
| PE20141906A1 (es) | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| JP6722453B2 (ja) | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | 抗不安薬組成物、製剤および使用方法 |
| JP6462663B2 (ja) | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en not_active Ceased
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Ceased
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106714789A (zh) | 2017-05-24 |
| JP2017524719A (ja) | 2017-08-31 |
| US20160045455A1 (en) | 2016-02-18 |
| EP3179993A4 (en) | 2018-03-28 |
| AU2015301782B2 (en) | 2020-09-03 |
| IL250490A0 (en) | 2017-03-30 |
| EP3179993B1 (en) | 2021-01-20 |
| MX2017001908A (es) | 2017-08-08 |
| IL279627A (en) | 2021-03-01 |
| WO2016025581A1 (en) | 2016-02-18 |
| KR20170040800A (ko) | 2017-04-13 |
| JP6545788B2 (ja) | 2019-07-17 |
| EP3179993A1 (en) | 2017-06-21 |
| AU2020281101A1 (en) | 2021-01-07 |
| US10098854B2 (en) | 2018-10-16 |
| AU2015301782A1 (en) | 2017-03-02 |
| CA2957926A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40462A (fr) | Méthode de traitement de la dépression | |
| IL279119A (en) | VAL66MET genotype-specific dosage regimens (SNP rs6265) and methods for treating depression | |
| MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| MX2017008184A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
| MY206629A (en) | Detection processes using sites of chromosome interaction | |
| MX2020013278A (es) | Analogos de nucleotidos. | |
| PH12016502563A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12016500660A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12015501423A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| MX2016017382A (es) | Metodos para preparar analogos de nucleotido sustituidos. | |
| PH12014502094B1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| LT3265102T (lt) | Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui | |
| FR3028512B1 (fr) | Procede d'hydrosilylation mettant en œuvre un catalyseur organique derive de germylene | |
| EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| PH12016500492B1 (en) | Pyridazinone compounds and uses thereof | |
| BR112017006680A2 (pt) | variantes de vírus influenza a | |
| HUE046116T2 (hu) | Biotin, demielinizációs neuropátiák kezelésére | |
| MX2016017124A (es) | Proceso para la preparacion de acidos 3-hidroxipicolinicos. | |
| WO2015109318A3 (en) | Therapeutic methods | |
| MX2017012027A (es) | Desaminacion de nucleosidos organofosforados. | |
| PH12016502592A1 (en) | 3'-substituted-abscisic acid derivatives | |
| TW201612142A (en) | Process for preparing 3-chloro-2-vinylphenol | |
| MX385963B (es) | Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease |